Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes

[1] Asthagiri AR(2009)Neurofibromatosis type 2 Lancet (London, England) 373 1974-1986

[2] Parry DM(2009)Neurofibromatosis type 2 (NF2): a clinical and molecular review Orphanet J Rare Dis 4 16-610

[3] Butman JA(2009)Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II] Genet Med 11 599-618

[4] Kim HJ(1992)A clinical study of type 2 neurofibromatosis Q J Med 84 603-885

[5] Tsilou ET(1996)The neuroimaging and clinical spectrum of neurofibromatosis 2 Neurosurgery 38 880-573

[6] Zhuang Z(2015)Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas Neuro-oncology 17 566-367

[7] Lonser RR(2009)Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 N Engl J Med 361 358-1337

[8] Evans DG(2017)Hearing optimisation in neurofibromatosis type 2: a systematic review Clin Otolaryngol 42 1329-101

[9] Evans DG(2005)VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate Otol Neurotol 26 98-175

[10] Evans DG(2015)Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells Cancer Biol Ther 16 170-266

[1] Asthagiri AR(2009)Neurofibromatosis type 2 Lancet (London, England) 373 1974-1986

[2] Parry DM(2009)Neurofibromatosis type 2 (NF2): a clinical and molecular review Orphanet J Rare Dis 4 16-610

[3] Butman JA(2009)Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II] Genet Med 11 599-618

[4] Kim HJ(1992)A clinical study of type 2 neurofibromatosis Q J Med 84 603-885

[5] Tsilou ET(1996)The neuroimaging and clinical spectrum of neurofibromatosis 2 Neurosurgery 38 880-573

[6] Zhuang Z(2015)Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas Neuro-oncology 17 566-367

[7] Lonser RR(2009)Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 N Engl J Med 361 358-1337

[8] Evans DG(2017)Hearing optimisation in neurofibromatosis type 2: a systematic review Clin Otolaryngol 42 1329-101

[9] Evans DG(2005)VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate Otol Neurotol 26 98-175

[10] Evans DG(2015)Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells Cancer Biol Ther 16 170-266